5 Must-Read Analyst Questions From Quest’s Q1 Earnings CallQuest Diagnostics delivered first quarter results that exceeded Wall Street’s revenue and profit expectations, driven by broad-based demand for its clinical ...
DGX Q1 Deep Dive: Organic Growth, Consumer Testing Momentum, and Advanced Diagnostics Drive OutlookHealthcare diagnostics company Quest Diagnostics (
NYSE:DGX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 9.2% year on ...
Quest’s (NYSE:DGX) Q1 CY2026 Sales Beat EstimatesHealthcare diagnostics company Quest Diagnostics (
NYSE:DGX) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.2% year on...
Quest (DGX) To Report Earnings Tomorrow: Here Is What To ExpectHealthcare diagnostics company Quest Diagnostics (
NYSE:DGX) will be reporting results this Tuesday before market open. Here’s what investors should know. Que...
2 S&P 500 Stocks Worth Your Attention and 1 We IgnoreThe S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Q4 Earnings Roundup: Quest (NYSE:DGX) And The Rest Of The Testing & Diagnostics Services SegmentThe end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
3 Cash-Producing Stocks That Fall ShortGenerating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
3 Mid-Cap Stocks with Warning SignsMid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...
3 Reasons to Avoid DGX and 1 Stock to Buy InsteadSince September 2025, Quest has been in a holding pattern, posting a small return of 4.5% while floating around $195.43. However, the stock is beating the S&...
1 Healthcare Stock with Exciting Potential and 2 We AvoidPersonal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
The Great Migration: Outpatient Care Stocks Surge as Aging Populations and AI Reshape American HealthcareAs of March 17, 2026, the American healthcare landscape is undergoing its most significant structural transformation in decades. The traditional hospital-centric model is rapidly giving way to a decentralized, outpatient-first ecosystem, fueled by an aging demographic often referred to as the "Silver Tsunami." This shift is not merely a matter
5 Insightful Analyst Questions From Quest’s Q4 Earnings CallQuest Diagnostics delivered a Q4 performance that exceeded Wall Street’s revenue and earnings expectations, prompting a positive market reaction. Management attributed this outcome to strong organic growth across physician, hospital, and consumer channels, with advanced diagnostics and recent partnerships like Fresenius Medical Care and Corewell Health contributing significant volume gains. CEO Jim Davis cited the company’s expansion in specialized testing—such as Alzheimer’s and autoimmune diagnostics—and collaborations that broadened geographic and health plan access as key drivers. Operational improvements, including automation and AI deployment, further supported productivity and customer experience gains.
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI EfficiencyOn February 11, 2026, the clinical laboratory landscape is recalibrating following a whirlwind 48 hours of financial and regulatory news. Quest Diagnostics (
NYSE: DGX), the nation’s leading provider of diagnostic information services, finds itself at the epicenter of this shift. Following a blowout fourth-quarter earnings report yesterday and a last-minute legislative reprieve regarding Medicare reimbursement [...]
DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin HeadwindsHealthcare diagnostics company Quest Diagnostics (
NYSE:DGX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.
Why Is Quest (DGX) Stock Soaring TodayShares of healthcare diagnostics company Quest Diagnostics (
NYSE:DGX)
jumped 6.8% in the afternoon session after the company reported strong fourth-quarter financial results and offered an upbeat forecast for 2026. For the fourth quarter, Quest's revenue grew 7.1% year-on-year to $2.81 billion, surpassing analyst estimates. Its adjusted earnings of $2.42 per share also came in ahead of expectations. Looking forward, the company's full-year 2026 revenue guidance was a notable highlight, coming in 3.3% above consensus estimates. The earnings guidance for the upcoming year also topped forecasts, signaling management's confidence in sustained performance.
